41888-21-5

Usage

Uses

Used in Pharmaceutical Synthesis:
2-Oxo-3-piperidinecarboxylic acid is used as a key building block for the synthesis of various pharmaceutical compounds, leveraging its structural and functional properties to create new and effective medications.
Used in Chemical Intermediates:
In the chemical industry, 2-Oxo-3-piperidinecarboxylic acid serves as an essential intermediate, facilitating the production of a range of chemical products through its reactivity and structural attributes.
Used in Therapeutic Applications:
2-Oxo-3-piperidinecarboxylic acid is used as a potential therapeutic agent for the treatment of various diseases and conditions, capitalizing on its pharmacological activities to offer new avenues for medical intervention.
Used in Drug Research and Development:
In the field of drug research and development, 2-Oxo-3-piperidinecarboxylic acid is utilized for its potential to contribute to the discovery and creation of novel drugs, enhancing the scope of treatment options available to patients.

InChI:InChI=1/C6H9NO3/c8-5-4(6(9)10)2-1-3-7-5/h4H,1-3H2,(H,7,8)(H,9,10)

Upstream product

• 3731-16-6 3-carboethoxy-2-pyridone 

Downstream Products

• 57073-81-1 3-(Phenylhydrazone) of 2,3-piperidinedione 
• 91720-57-9 2,3-piperidinedione 3-(5'-methoxy-2'-bromophenyl)hydrazone 
• 133859-76-4 3-(5-Chloro-2-methylphenylhydrazone) of 2,3-piperidinedione 
• 94850-46-1 3-(2-Methyl-5-nitrophenylhydrazone) of 2,3-piperidinedione 
• 94850-62-1 3-(2,5-Dimethylphenylhydrazone) of 2,3-piperidinedione 
• 91089-98-4 piperidine-2,3-dione-3-(4-chloro-phenylhydrazone) 
• 104742-98-5 2,3-dioxopiperidine 3-(p-methoxyphenyl)hydrazone 
• 721-58-4 piperidine-2,3-dione-3-(4-fluoro-phenylhydrazone) 
• 110047-11-5 piperidine-2,3-dione-3-(4-methylsulfanyl-phenylhydrazone) 
• 156312-11-7 Bauerine C 

Relevant academic research and scientific papers

1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF

The present invention relates to 1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indole derivative compounds and uses thereof. In particular, compounds of the invention have antibacterial activity and/or are capable of re-sensitizing methicillin-resistant Staphylococcus aureus to a P-lactam antibiotic or a combination of a P-lactam antibiotic and a P-lactamase inhibitor. The present invention also relates to a method for producing and using said compounds.

Gram-scale, chemoselective synthesis of N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-2-oxopiperidine-3-carboxamide (HIOC)

N-[2-(5-Hydroxy-1H-indol-3-yl)ethyl]-2-oxopiperidine-3-carboxamide (HIOC) is a potent activator of the TrkB receptor in mammalian neurons and of interest because of its potential therapeutic uses. In the absence of a commercial supply of HIOC, we sought to produce several grams of material. However, a synthesis of HIOC has never been published. Herein we report the preparation of HIOC by the chemoselective N-acylation of serotonin, without using blocking groups in the key acylation step.

Optical evodiamine derivatives: Asymmetric synthesis and antitumor activity

Evodiamine and its derivatives have an asymmetric center at the C13b position. Herein, isomers of evodiamine derivatives 2 and 3 were obtained by straightforward asymmetric total synthesis. Their inhibitory activities toward topoisomerases I and II and th

New tricks for an Old natural product: Discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations

Evodiamine is a quinazolinocarboline alkaloid isolated from the fruits of traditional Chinese herb Evodiae fructus. Previously, we identified N13-substituted evodiamine derivatives as potent topoisomerase I inhibitors by structure-based virtual screening and lead optimization. Herein, a library of novel evodiamine derivatives bearing various substitutions or modified scaffold were synthesized. Among them, a number of evodiamine derivatives showed substantial increase of the antitumor activity, with GI50 values lower than 3 nM. Moreover, these highly potent compounds can effectively induce the apoptosis of A549 cells. Interestingly, further computational target prediction calculations in combination with biological assays confirmed that the evodiamine derivatives acted by dual inhibition of topoisomerases I and II. Moreover, several hydroxyl derivatives, such as 10-hydroxyl evodiamine (10j) and 3-amino-10-hydroxyl evodiamine (18g), also showed good in vivo antitumor efficacy and low toxicity at the dose of 1 mg/kg or 2 mg/kg. They represent promising candidates for the development of novel antitumor agents.

Total syntheses of the chlorinated β-carboline alkaloids bauerine A, B, and C

The first total synthesis of the chlorinated 1-oxo-β-carboline alkaloid bauerine C based on a Japp-Klingemann reaction is reported. An intermediate of this synthesis was converted to the fully aromatic β-carboline bauerine B, and the related alkaloid baue

Syntheses of 7-fluoro- and 6,7-difluoroserotonin and 7-fluoro- and 6,7-difluoromelatonin

The Abramovitch adaption of the Fischer indole synthesis gave low yields of 7-fluoro-5-methoxytryptamine due in part to decomposition during the required decarboxylation step. Therefore, 7-fluoro- and 6,7-difluoro-5-methoxytryptamines were prepared by rea

Anti-Cytokine Heterocyclic Compounds

Heterocyclic compounds and analogues thereof and their use as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by

Novel inhibitors of acetyl- and butyrylcholinesterase derived from the alkaloids dehydroevodiamine and rutaecarpine

Derived from the structures of the alkaloids rutaecarpine and dehydroevodiamine (DHED), and the long-known acetylcholinesterase (AChE) inhibitor tacrine, respectively, novel compounds were synthesised, including: 13-methyl-5,8-dihydro-6H-isoquino[1,2-b]quinazolin-13-ium chloride (12), (8Z)-5,6-dihydro-8H-isoquino[1,2-b]quinazolin-8-imine (13), 5,8-dihydro-6H- isoquino[1,2-b]quinazoline (15a), 13-methyl-5,8-dihydro-6H-isoquino[1,2-b] quinazolin-13-ium chloride (16), 5,7,8,13-tetrahydroindolo [2′,3′:3, 4]pyrido[2,1-b]quinazoline (17), and N-(2-phenylethyl)-N-[(12Z)-7,8,9,10- tetrahydroazepino [2,1-b]quinazolin-12(6H)-ylidene]amine (20), respectively. In a first step to evaluate their possible applicability for antiamnesic therapy, the inhibition of AChE and butyrylcholinesterase (BChE) were determined: compounds 13, 15a, 17, and 20 are moderate or strong inhibitors of ChE, the latter two compounds show a 10-fold higher affinity to BChE. Compound 12 is a moderate inhibitor of AChE showing selectivity towards this enzyme. (Chemical presented)

Isolation and synthesis of a new aromatic compound, brefelamide, from Dictyostelium cellular slime molds and its inhibitory effect on the proliferation of astrocytoma cells

We have explored the diversity of secondary metabolites produced by cellular slime molds to examine the possible use of such cellular slime molds as a resource for novel drug development. A new aromatic amide, brefelamide (1), was isolated from methanol e

Preparation of 7-methoxytryptamine

7-Methoxytryptamine (6a) was prepared from cheap and easily available starting materials by using the Abramovitch-Shapiro method